James S Scott - AstraZeneca | 人才画像

基本信息

浏览量：24

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 197 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Selective Estrogen Receptor Degraders (serds) and Covalent Antagonists (sercas): a Patent Review (july 2021-December 2023)

James S Scott,Teresa C M Klinowska

Expert opinion on therapeutic patentsno. 5 (2024): 333-350

引用0浏览0WOS引用

Figure 1 from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

crossref（2024）

引用0浏览0引用

Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis

Camila Aparicio,Zachary Willis,Mari M. Nakamura,Joshua Wolf, Cordell Little,Gabriela M. Maron,Paul K. Sue,Brenda Anosike, Christine Miller,Laura L. Bio,Prachi Singh,Scott H. James,Carlos R. Oliveira

Journal of the Pediatric Infectious Diseases Societyno. 7 (2024): 352-362

引用0浏览0WOS引用

Longitudinal Monitoring of the Effects of Anti-Adenoviral Treatment Regimens in a Permissive in Vivo Model

Ann E. Tollefson,Anna Cline-Smith,Jacqueline F. Spencer,Baoling Ying,Dawn M. Reyna,Elke Lipka,Scott H. James,Karoly Toth

Virusesno. 8 (2024): 1200-1200

引用0浏览0WOS引用

Structural and Physicochemical Features of Oral PROTACs

Markus Schade,James S. Scott,Thomas G. Hayhow,Andy Pike,Ina Terstiege, Marie Ahlqvist,Johan R. Johansson,Coura R. Diene,Charlene Fallan,Amber Y. S. Balazs,Elisabetta Chiarparin,David Wilson

Journal of Medicinal Chemistryno. 15 (2024): 13106-13116

引用0浏览0WOS引用

Figure 2 from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER⁺ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

crossref（2024）

引用0浏览0引用

Discovery and in Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity

JOURNAL OF MEDICINAL CHEMISTRYno. 16 (2024): 13604-13638

引用0浏览0WOS引用

Figure 4 from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

crossref（2024）

引用0浏览0引用

Metabolism-driven in Vitro/in Vivo Disconnect of an Oral ERɑ VHL-PROTAC

COMMUNICATIONS BIOLOGYno. 1 (2024)

引用0浏览0WOSNATURE引用

Supplementary Data from The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

crossref（2024）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn